Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab - Eckstein, M; Erben, P; Kriegmair, MC (Eur J Cancer, 2019)